IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+5.25%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$358M
AUM Growth
+$358M
(+11%)
Cap. Flow
+$30.7M
Cap. Flow
% of AUM
8.56%
Top 10 Holdings %
Top 10 Hldgs %
49.91%
Holding
70
New
7
Increased
17
Reduced
7
Closed
6
Top Buys
| 1 |
Amgen
AMGN
|
$18.1M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$10.4M |
| 3 |
Harmony Biosciences
HRMY
|
$9.99M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$6.88M |
| 5 |
Vera Therapeutics
VERA
|
$5.57M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$35.8M |
| 2 |
Travere Therapeutics
TVTX
|
$5.35M |
| 3 |
Illumina
ILMN
|
$4.65M |
| 4 |
uniQure
QURE
|
$3.08M |
| 5 |
PTC Therapeutics
PTCT
|
$2.47M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Krystal Biotech
KRYS
$4.27B
| $4.88M | 1.36% | 61,000 +16,000 | +36% | +$1.28M |
|
27
Gilead Sciences
GILD
$140B
| $4.78M | 1.33% | 57,584 | – | – |
|
28
AstraZeneca
AZN
$248B
| $4.51M | 1.26% | 65,000 | – | – |
|
|
29
PTC Therapeutics
PTCT
$3.92B
| $4.5M | 1.26% | 93,000 -51,000 | -35% | -$2.47M |
|
30
Erasca
ERAS
$445M
| $4.28M | 1.19% | +1,426,000 | New | +$4.28M |
|
31
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.06M | 1.13% | 216,000 +116,000 | +116% | +$2.18M |
|
32
Genmab
GMAB
$15.3B
| $3.32M | 0.93% | +88,000 | New | +$3.32M |
|
|
33
Travere Therapeutics
TVTX
$1.56B
| $3.17M | 0.88% | 141,019 -238,000 | -63% | -$5.35M |
|
34
Ascendis Pharma
ASND
$11.8B
| $3.15M | 0.88% | 29,400 | – | – |
|
35
Zai Lab
ZLAB
$3.68B
| $2.63M | 0.73% | 78,958 | – | – |
|
36
Jazz Pharmaceuticals
JAZZ
$7.75B
| $2.51M | 0.7% | 17,200 | – | – |
|
37
Caribou Biosciences
CRBU
$174M
| $2.43M | 0.68% | 457,892 +200,000 | +78% | +$1.06M |
|
38
Apellis Pharmaceuticals
APLS
$3.48B
| $2.09M | 0.58% | 31,700 | – | – |
|
|
KRTX
39
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $2M | 0.56% | +11,000 | New | +$2M |
|
40
Denali Therapeutics
DNLI
$2.23B
| $1.99M | 0.56% | 86,575 +48,575 | +128% | +$1.12M |
|
41
NovoCure
NVCR
$1.38B
| $1.92M | 0.54% | 32,000 | – | – |
|
42
Legend Biotech
LEGN
$6.41B
| $1.83M | 0.51% | 38,000 | – | – |
|
43
Guardant Health
GH
$8.41B
| $1.75M | 0.49% | 74,500 | – | – |
|
44
Halozyme
HALO
$8.56B
| $1.74M | 0.48% | +45,500 | New | +$1.74M |
|
45
Mirum Pharmaceuticals
MIRM
$3.71B
| $1.62M | 0.45% | 67,500 | – | – |
|
46
CRISPR Therapeutics
CRSP
$4.71B
| $1.55M | 0.43% | 34,200 | – | – |
|
47
Ionis Pharmaceuticals
IONS
$6.8B
| $1.54M | 0.43% | +43,000 | New | +$1.54M |
|
48
Rocket Pharmaceuticals
RCKT
$354M
| $1.08M | 0.3% | 63,000 | – | – |
|
|
IMAB
49
I-MAB
IMAB
$340M
| $1.07M | 0.3% | 310,499 | – | – |
|
50
Novavax
NVAX
$1.21B
| $925K | 0.26% | 132,500 | – | – |
|